BLB&B Advisors LLC Sells 25,375 Shares of Pfizer Inc. (NYSE:PFE)

BLB&B Advisors LLC decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 33.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,414 shares of the biopharmaceutical company's stock after selling 25,375 shares during the period. BLB&B Advisors LLC's holdings in Pfizer were worth $1,277,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Brighton Jones LLC raised its position in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the period. Proficio Capital Partners LLC lifted its position in Pfizer by 2,193.2% during the fourth quarter. Proficio Capital Partners LLC now owns 225,584 shares of the biopharmaceutical company's stock valued at $5,985,000 after purchasing an additional 215,747 shares during the period. Noble Wealth Management PBC purchased a new stake in Pfizer in the fourth quarter worth approximately $31,000. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the 4th quarter worth approximately $28,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PFE has been the topic of several recent research reports. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Price Performance

NYSE PFE traded up $0.79 during trading hours on Tuesday, reaching $25.03. The company's stock had a trading volume of 59,108,874 shares, compared to its average volume of 41,457,239. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $142.30 billion, a price-to-earnings ratio of 18.14, a PEG ratio of 0.88 and a beta of 0.57. The firm's 50-day moving average price is $23.51 and its 200-day moving average price is $24.83.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the business posted $0.82 earnings per share. The company's quarterly revenue was down 7.8% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.87%. Pfizer's dividend payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.